Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,709 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depression Disorder Clear all
Completed Phase 4 Interventional Results available

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 3:26 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

International Study to Predict Optimised Treatment - in Depression

NCT00693849
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Sertraline, Venlafaxine-XR
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
13
States / cities
Colton, California • Mission Viejo, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 4 Interventional Results available

Vilazodone for Treatment of Geriatric Depression

NCT01608295
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone; Viibryd, Paroxetine; Paxil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 4 Interventional

Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder

NCT00956514
View directory record Official record
Conditions
Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

NCT06029426
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NMRA-335140, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
64
States / cities
Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

NCT05327699
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT01110902
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional

Diet and Depression

NCT06252701
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
Interventions
Reduction of Ultra-processed foods
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Reward Function and Therapy for Late-Life Depression

NCT03688139
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Engage Therapy, Supportive Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 10, 2026, 3:26 AM EDT
Terminated Phase 3 Interventional

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

NCT06011577
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Levomecor Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Dothan, Alabama • Homewood, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional

Dose-Response Effect Exercise and Depression

NCT06166095
View directory record Official record
Conditions
Depression
Interventions
high-dose, Walking attention control, moderate-dose
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment

NCT02385786
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mindfulness-Based Cognitive Therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 4 Interventional Results available

Study Using Pregnenolone to Treat Bipolar Depression

NCT01409096
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jun 10, 2026, 3:26 AM EDT
Terminated Not applicable Interventional Results available

A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans

NCT03489122
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder
Interventions
yoga, walking
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Terminated Not applicable Interventional Results available

Effects of Amygdala Neurofeedback on Depressive Symptoms

NCT02709161
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS
Device
Lead sponsor
Kymberly Young
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Therapist-Guided Smartphone-Delivered CBT for MDD

NCT05386329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mindset: Therapist-guided smartphone-delivered CBT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jun 10, 2026, 3:26 AM EDT
Withdrawn No phase listed Observational

Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment

NCT02962154
View directory record Official record
Conditions
Ischemia, Stress, Mental
Interventions
Coronary CT Angiography, Mood Symptom Scale, Anxiety Symptom Scale, Chronic Stress Inventories, Psychosocial Function Questionnaires, General Health and quality of life questionnaires, Magnetic Resonance Imaging
Radiation · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Brain Connectivity and Response to Tai Chi in Geriatric Depression

NCT02460666
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tai-Chi-Chih (TCC), Health Education and Wellness Classes (HEW)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497
View directory record Official record
Conditions
Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions
escitalopram
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 10, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression

NCT05772702
View directory record Official record
Conditions
Depression, Major Depressive Disorder, tACS
Interventions
Closed-loop tACS
Device
Lead sponsor
Electromedical Products International, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 10, 2026, 3:26 AM EDT